What’s in a Name? Contentious Fight Over Biosimilars Coming to a Head
Friday, June 12, 2015
Source: THE WALL STREET JOURNAL
What’s in a name?
A contentious debate over identifying biosimilars may finally be coming to a head. These drugs are designed to emulate expensive biologics and are forecast to save billions of dollars in U.S. health-care costs over the next decade. But finding the best approach for naming biosimilars has vexed regulators and divided drug makers amid sparring over patient safety and the potential for big profits.